The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
MateosMV, HernandezJM, HernandezMT, Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165–2172.
3.
MateosMV, HernandezJM, HernandezMT, Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93(4):560–565.
4.
San MiguelJF, SchlagR, KhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
5.
DimopoulosMA, RichardsonPG, SchlagR, VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA Study. J Clin Oncol. 2009;27(36):6086–6093.
6.
MateosMV, OriolA, Martinez-LopezJ, Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomized trial. Lancet Oncol. 2010;11(10):934–941.
7.
MorabitoF, GentileM, MazzoneC, Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118(22):5759–5766.
8.
OgawaY, SuzukiK, SakaiAPhase1/11 study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Sci. 2013;104(7): 912–919.
9.
NiesvizkyR, FlinnIW, RifkinR, Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract 478]. Blood. 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/478. Accessed November 14, 2014.
10.
MateosMV, RichardsonPG, ShiH, Higher cumulative bortezomib dose results in better overall survival (OS) in patients with previously untreated multiple myeloma (MM) receiving bortezomib-melphalan-prednisone (VMP) in the phase 3 VISTA study [abstract 1968]. Proc Am Soc Hematol. 2013. http://www.bloodjournal.org/content/122/21/1968. Accessed September 8, 2014.
11.
KimK, LeeM, KimHJ, Observational study of VMP (bortezomib, melphalan, prednisolone) regimen for newly diagnosed Korean myeloma patients who are not eligible for transplantation [abstract 5379]. Proc Am Soc Hematol. 2013. http://www.bloodjournal.org/content/122/21/5379. Accessed September 8, 2014.
12.
NiesvizkyR, FlinnI, RifkinRM, Efficacy and safety of three bortezomib-based induction and maintenance regimens in previously untreated, transplant-ineligible multiple myeloma (MM) patients (Pts): Final results from the randomized, phase 3b, US community-based UPFRONT study (NCT00507416) [abstract 1966]. Proc Am Soc Hematol. 2013. http://www.bloodjournal.org/content/122/21/1966. Accessed September 8, 2014.
13.
MateosMV, Martinez-LópezJ, HernandezMT, Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 trial [abstract 403]. Proc Am Soc Hematol. 2013. http://www.bloodjournal.org/content/122/21/403. Accessed: September 8, 2014.
14.
LaroccaA, CavalloF, MagarottoVReduced doseintensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age [abstract 539]. Proc Am Soc Hematol. 2013. http://www.bloodjournal.org/content/122/21/539. Accessed September 8, 2014.
MoreauP, PylypenkoH, GrosickiS, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomized, phase 3, noninferiority study. Lancet Oncol. 2011;12(6):431–440.
17.
KohY, LeeSY, KimI, Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol. 2014;74(3):653–657.
18.
HeskethPJ, KrisMG, GrunbergSM, Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–109.
BaschE, PrestrudAA, HeskethPJAntiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update: 2011. J Clin Oncol. 2011;29(31):4189–4198.
SmithTJ, KhatcheressianJ, LymanGH, 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
LoRussoPM, VenkatakrishnanK, RamanathanRK, Pharmocokinetics and safety of bortezomib in patients with advances malignancies and varying degrees of liver dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954–2963.
